Key Takeaways:
- Strategic Collaboration: Carthera partners with Accord Healthcare for the development and supply of carboplatin.
- Innovative Medical Device: SonoCloud®, an ultrasound-based device, poised to transform the treatment of recurrent glioblastoma.
- Focus on Patient Outcomes: This partnership aims to facilitate regulatory approval, ensuring carboplatin’s supply for trials and future commercialization.
A Milestone in Brain Disorder Treatment
Paris, France, November 6, 2023 – Carthera, an innovative medtech company born from Sorbonne University, has announced a strategic collaboration with Accord Healthcare Limited, a leading pharmaceutical company. This partnership is set to enhance the development, manufacturing, and commercialization of carboplatin in conjunction with Carthera’s groundbreaking SonoCloud® system for treating recurrent glioblastoma (rGBM), a severe form of brain cancer.
Carthera’s SonoCloud®: Pioneering in Brain Health
Transforming Glioblastoma Treatment
Carthera’s SonoCloud® represents a major advancement in the field of brain disorders. This proprietary implantable device is designed to open the Blood-Brain Barrier (BBB) using low-intensity pulsed ultrasound (LIPU), facilitating effective chemotherapy delivery to brain tumors. This novel approach has the potential to significantly improve treatment efficacy for glioblastoma, a disease with a median survival rate of around 15 months post-diagnosis.
The Collaboration’s Impact
Enhancing Carboplatin’s Role
The partnership between Carthera and Accord Healthcare involves the development and supply of carboplatin, a crucial component in the SonoCloud solution for rGBM treatment. By securing the supply of carboplatin, this collaboration strengthens the SonoCloud system’s profile, aiding in the regulatory approval process and ensuring its availability for future trials and commercialization.
A Synergistic Approach to Innovation
Accelerating Market Authorization
Frédéric Sottilini, CEO of Carthera, expresses enthusiasm about the collaboration with Accord Healthcare. He underscores their mutual commitment to advancing SonoCloud technology and improving outcomes for patients with glioblastoma. The partnership is aimed at bolstering their chances of obtaining marketing authorization for SonoCloud in the upcoming years.
Accord Healthcare’s Contribution
Expanding Carboplatin Applications
Alex Falgas, VP Business Development & Portfolio, Europe & MENA at Accord Healthcare, highlights the significance of extending their carboplatin franchise to glioblastoma treatment. This collaboration aligns with Accord’s dedication to supplying innovative products and enhancing patient outcomes, particularly for diseases with high unmet medical needs.
About SonoCloud®
A Breakthrough in Medical Technology
SonoCloud is an innovative medical device developed by Carthera. It employs ultrasound to temporarily increase the permeability of blood vessels in the brain, thereby enhancing the delivery of therapeutic molecules. The device, invented by Pr. Alexandre Carpentier and developed in collaboration with LabTAU, INSERM in Lyon, France, represents a potential new treatment option for various brain conditions, including tumors and Alzheimer’s disease. The safety and approval of SonoCloud for investigational use are currently under review by regulatory authorities.
About Accord Healthcare Ltd
A Leader in Pharmaceutical Innovation
Headquartered in the UK, Accord Healthcare Ltd. is among the fastest-growing pharmaceutical companies in Europe. With a significant presence in the oncology sector and a commitment to improving product access, Accord is shaping the future of healthcare. Their portfolio includes over 40 oncology treatments and plans to introduce 20 more in the next five years.
About Carthera
Advancing Ultrasound-Based Medical Devices
Carthera, a spin-off from AP-HP Paris and Sorbonne University, is a clinical-stage medtech company focusing on developing ultrasound-based medical devices for brain disorders. Founded in 2010, Carthera has received support from various national and international agencies, reflecting its commitment to innovative healthcare solutions.
Sign up to our newsletter & get the most important monthly insights from around the world.
Ready to Amplify Your Brand with Business Today?
Discover the power of sponsored articles and partnerships to reach decision-makers, professionals, and a dynamic audience. Learn more about our advertising opportunities and connect with us today!
Click here to explore our Promotion & Sponsored Articles page.
Are you looking to make an impact? Contact us at pitch@businesstoday.news to get started!
